Paveron

Paveron is an early-stage biotechnology company focused on the discovery and development of next-generation targeted protein degradation (TPD) therapies. The company utilizes a proprietary platform to identify and optimize small molecule degraders, including molecular glues and PROTACs, designed to eliminate disease-causing proteins that are otherwise difficult to target with traditional inhibitors. Headquartered in San Diego, Paveron aims to address significant unmet needs in oncology and immunology by leveraging the body's natural protein disposal system. The company is currently in the pre-clinical stage, advancing a pipeline of novel candidates toward IND-enabling studies.